AR065188A2 - Piperidinas sustituidas, preparacion farmaceutica y uso de dichas piperidinas para preparar medicamentos - Google Patents
Piperidinas sustituidas, preparacion farmaceutica y uso de dichas piperidinas para preparar medicamentosInfo
- Publication number
- AR065188A2 AR065188A2 ARP080100485A ARP080100485A AR065188A2 AR 065188 A2 AR065188 A2 AR 065188A2 AR P080100485 A ARP080100485 A AR P080100485A AR P080100485 A ARP080100485 A AR P080100485A AR 065188 A2 AR065188 A2 AR 065188A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- alq
- hydrogen
- bond
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 2
- 239000005977 Ethylene Substances 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- -1 acenaphthyl Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001925 cycloalkenes Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de formula (1) o (2) donde R es alquenilo C2-8, alquilo C1-8, alquinilo C2-8, alquilo-C0-8-carbonil-amino-alquilo-C1-8, cicloalquilo-C3-8-alquilo-C0-8, aIquiIo-C1-8-sulfonil-alquiIo-C1-8, carbamoil-alquilo-C0-8 no alquilado o N-mono- o N,N-di alquilado-C1-8, carboxil-alquilo-C0-8 no alquilado u O-alquilado-C1-8, ureido-alquilo-C1-8 no alquilado o N- y/o N'- mono-, di- o tri-alquilado-C1-8, o heterocicIilcarbonil-alquilo C0-8, donde cada uno de dichos radicales está sustituido con 1 a 4 alcoxi C1-8 o hidroxilo; R1 es arilo o heterociclilo; R2 es acenaftilo, ciclohexilo, diazinilo, furilo, imidazolilo, naftilo, oxadiazolilo, oxazolilo, fenilo, pirazinilo, piridilo, pirimidinilo, pirrolilo, oxopiridinilo, tetrazolilo, tienilo o triazolilo, donde cada uno de dichos radicales puede estar sustituido con 1 a 3 grupos alcanoiloxi-C1-8-alquilo-C1-8, alqueniloxi C2-8, alcoxi C1-8, alcoxi-C1-8-alcoxi-C1-8, alcoxi-C1-8-alcoxi-C1-8-alquilo-C1-8, alcoxi-C1-8-alquilo-C1-8, alcoxicarbonilo C1-8, alcoxicarboniloxi-C1-8-alquilo-C1-8, alquilo C1-8, carboxi-alquilo-C1-8, alcoxi-C1-8-alquilsulfanilo-C1-8, alquilsulfanilo C1-8, alquilsulfanilo-C1-8-alcoxi-C1-8, alquilsulfanilo-C1-8-alcoxi-C1-8-alquilo-C1-8, alquilsulfanilo- C1-8-alquilo-C1-8, ciano, ciano-alquilo-C1-8, cicloalquilo-C3-8-alcoxi-C0-6-alcoxi-C1-8, alcoxi-C1-6-alquilo-C0-6-cicloalquilo-C3-8-alcoxi-C0-6-aIquilo-C1-8, cicloalquilo-C3-8-alcoxi-C0-60-aIquilo-C1-8; halo-alquilo-C1-8; halogeno; hidroxi-alquilo- C1-8; hidroxilo; oxido; trifluormetoxi o trifluormetilo; o un grupo alquilendioxi C1-8; y/o con un radical L1-T1 -L2-T2-L3-T3-L4-T4-L5-U; donde L1, L2, L3, L4 y L5 son, de manera independiente, un enlace, alquileno C1-8, alquenileno C2-8 o alquinileno C2-8; cicloalqueno C3-8, o están ausentes; T1, T2, T3 y T4 son, de manera independiente (a) un enlace o están ausentes; o son uno de los grupos (b) -CH(OH)-; (c) -CH(OR6)-; (d) -CH(NR5R6)-; (e) -CO-; (f) -CR7R8-; (g) -O- o -NR6-; (h) - S(O)0-2-; (i) -SO2NR6-; (j) -NR6SO2-; (k) -CONR6-; (l) -NR6CO-; (m) -O-CO-; (n) -CO-O-; (o) -O-CO-O-; (p) -O-CO-NR6-; (q) -N(R6)-CO-N-(R6)-; (r) -N(R6)-CO-O-; (s) pirrolidinileno, piperidinileno o piperazinileno; (t) -C(R11)(R12)-; donde los enlaces que comienzan a partir de (b)-(t) llevan a un átomo de carbono aromático o saturado del grupo adyacente, si el enlace comienza a partir de un heteroátomo, y donde no están presentes más de dos grupos (b)-(f), tres grupos (g)-(h) y un grupo (i)-(t); R3 es hidrogeno, hidroxilo, alcoxi C1-8 o alqueniloxi C2-8; R4 es hidrogeno, alquenilo C2-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, alcoxi C1-8-alcoxi C1-8, alquilo C1-8, opcionalmente (N-alquilo-C1-8)-alcoxicarbonilo-C1-8-amino-alcoxi-C1-8, opcionalmente (N-alquilo C1-8)-alquilcarbonilo-C1-8-amino-alcoxi-C1-8, opcionalmente (N-mono- o N,N-di-alquilo-C1-8)-amino-alcoxi-C1-8, bencilo, cicloalquiIoxi-C3-8, cicloalquiloxi-C3-8-aIcoxi-C1-8, heterociclil-alcoxi C0-8, heterocicliloxi- alcoxi- C1-8, hidroxi, hidroxi-alcoxi-C1-8-alcoxi-C1-8, hidroxi-alquilo-C1-8, oxo o un grupo R4a-Z1-X1- donde R4a es (a) H; (b) alquilo C1-8-; (c) alquenilo C2-8-; (d) hidroxi-alquilo-C1-8-; (e) polihidroxi-alquilo-C1-8-; (f) alquilo-C1-8-O-alquilo-C1-8-; (g) arilo-; (h) heterociclilo; (i) arilalquilo-; (j) heterociclilalquilo-; (k)ariloxialquilo-; (l) heterocicliloxialquilo-; (m) (R5,R6)N-(CH2)1-3-; (n) (R5,R6)N-; (o) alquilo-C1-8-S(O)0-2-, (p) aril-S(O)0-2-; (q) heterociclil-S(O)0-2-; « HO-SO3 o sus sales; (s) H2N-C(NH)-NH-; (t) NC-; y los enlaces que comienzan a partir de (n)-(t) conducen a un átomo de carbono del grupo adyacente y este átomo de carbono está saturado si el enlace comienza a partir de un heteroátomo; Z1 es (a) un enlace; está ausente; o es uno de los grupos: (b) -alquileno C1-8-; (c) -alquenileno C2-8-; (d) -O-, -N(R11)-, -S(O)0-2-; (e) -CO-; (f) -O-CO-; (g) -O-CO-O-; (h) -O-CO-N(R11)-; (i)-N(R11)-CO-O-; (j) -CO-N(R11)-; (k) -N(R11)-CO-; (l) -N(R11)-CO-N(R11)-; (m) - CH(OR9)-; y los enlaces que comienzan a partir de (d) y (f)-(m) conducen a un átomo de carbono del grupo adyacente y este átomo de carbono está saturado si el enlace comienza a partir de un heteroátomo; X1 es (a) un enlace; está ausente; o es uno de los grupos (b) -O-; (c) -N(R11)-; (d) -S(O)0-2; (e) -(CH2)1-3-; o R3 y R4 en la formula (1) juntos son un enlace; R5 y R6 son, de manera independiente, hidrogeno, alquilo C1-8, alquenilo C2-8, aril-alquilo C1-8 o acilo; o junto con el átomo de N al que están unidos, son un anillo heterocíclico de 5 o 6 miembros que puede contener un átomo de N, O o S, o un grupo -SO- o -SO2-, y el átomo de N adicional puede estar opcionalmente sustituido con radicales alquiloC1-8; R7 y R8, junto con el átomo de carbono al que están unidos, son un anillo de 3 a 7 miembros que puede contener uno o dos átomos -O- o -S- o grupos -SO- o -SO2-: R9 es hidrogeno, alquilo C1-8, alcoxi-C1-8-alquilo-C1-8, acilo o arilalquilo; R10 es carboxialquilo, alcoxicarbonilalquilo, alquilo o hidrogeno; R11 es hidrogeno o alquilo C1-8; R12 es H o alquilo C1-8; Q es etileno o está ausente (formula 1), o es etileno o metileno (formula 2); U es hidrogeno, alquilo C1-8, ciano, cicloalquilo C3-8 opcionalmente sustituido, arilo o heterociclilo; W es oxigeno o azufre; X es un enlace, oxigeno o azufre, o es un grupo >CH-R11, >CHOR9, -O-CO-, >CO, >C=NOR10, -O-CHR11- o -O-CHR11-CO-NR9-, y el enlace que comienza a partir de un átomo de oxigeno o azufre conduce a un átomo de carbono saturado del grupo Z o a R1; Z es alquileno C1-8, alquenileno C2-8, hidroxialquilideno-C1-8-, -O-, -S-, -O-alq-, -S-alq-, -alq-O-, -alq-S- o -alq-NR9-, donde alq es alquileno C1-8 y donde (a) si Z es -O- o -S-, X es >CH-R11, y o bien R2 contiene un sustituyente L1-T1-L2-T2-L3-T3-L4-T4-L5-U, o R4 es un sustituyente diferente de hidrogeno como se define con anterioridad; (b) si Z es -O-alq- o -S-alq-, X es >CH-R11; y (c) si X es un enlace, Z es alquenileno C2-8, -alq-O- o - alq-S-; m en 0 o 1; n es 0 o 1; o una sal o profármaco de dicho compuesto; o donde uno o más átomos se reemplazan por sus isotopos estables, no radiactivos; preparacion farmacéutica y uso de dichas piperidinas para preparar medicamentos. Estos compuestos son utiles en el tratamiento y prevencion de la hipertension, insuficiencia cardíaca, insuficiencia renal y accidente cardiovascular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66655605P | 2005-03-31 | 2005-03-31 | |
| US75085305P | 2005-12-16 | 2005-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065188A2 true AR065188A2 (es) | 2009-05-20 |
Family
ID=36586065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101217A AR055756A1 (es) | 2005-03-31 | 2006-03-29 | Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos |
| ARP080100485A AR065188A2 (es) | 2005-03-31 | 2008-02-05 | Piperidinas sustituidas, preparacion farmaceutica y uso de dichas piperidinas para preparar medicamentos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101217A AR055756A1 (es) | 2005-03-31 | 2006-03-29 | Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20100029628A1 (es) |
| EP (1) | EP1863803B1 (es) |
| JP (2) | JP2008534558A (es) |
| AR (2) | AR055756A1 (es) |
| AT (1) | ATE479681T1 (es) |
| BR (2) | BRPI0621969A2 (es) |
| CA (1) | CA2601702A1 (es) |
| DE (1) | DE602006016573D1 (es) |
| IL (2) | IL186130A0 (es) |
| PL (1) | PL1863803T3 (es) |
| PT (1) | PT1863803E (es) |
| TW (2) | TW200833687A (es) |
| WO (1) | WO2006103277A2 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010323B (zh) | 2004-08-25 | 2010-06-16 | 埃科特莱茵药品有限公司 | 作为肾素抑制剂的双环壬烯衍生物 |
| TW200833687A (en) * | 2005-03-31 | 2008-08-16 | Speedel Experimenta Ag | Substituted piperidines |
| GEP20115206B (en) | 2005-05-27 | 2011-04-26 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| JP5420398B2 (ja) | 2006-05-19 | 2014-02-19 | アッヴィ・バハマズ・リミテッド | Ｃｎｓ活性縮合ビシクロ複素環置換アザ二環式アルカン誘導体 |
| TW200815425A (en) * | 2006-06-08 | 2008-04-01 | Speedel Experimenta Ag | 2,5-disubstituted piperidines |
| TW200821303A (en) * | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| EP1958634A3 (en) * | 2007-02-14 | 2008-09-24 | Speedel Experimenta AG | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease |
| TW200922596A (en) * | 2007-10-25 | 2009-06-01 | Speedel Experimenta Ag | 4,4-disubstituted piperidines |
| KR20100075590A (ko) * | 2007-11-02 | 2010-07-02 | 노파르티스 아게 | 레닌 억제제로서의 4,4-이치환된 피페리딘 |
| KR20100095605A (ko) | 2007-12-19 | 2010-08-31 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이시클릭 헤테로시클릭 유도체 |
| EP2250166A1 (en) * | 2008-02-08 | 2010-11-17 | Novartis AG | Substituted piperidines as renin inhibitors |
| KR20100135737A (ko) | 2008-02-08 | 2010-12-27 | 노파르티스 아게 | 레닌 억제제로서의 치환된 피페리딘 |
| JP4790871B2 (ja) | 2008-05-05 | 2011-10-12 | メルク フロスト カナダ リミテツド | レニン阻害剤としての３，４−置換ピペリジン誘導体 |
| EP2163245A1 (en) | 2008-09-10 | 2010-03-17 | Novartis Ag | Renin inhibitors for the treatment of psoriasis |
| US8389731B2 (en) * | 2009-05-15 | 2013-03-05 | Northwestern University | Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase |
| TWI461422B (zh) | 2009-06-24 | 2014-11-21 | Sumitomo Dainippon Pharma Co Ltd | Ｎ－取代－環狀胺基衍生物 |
| WO2016112387A1 (en) * | 2015-01-09 | 2016-07-14 | J.W. Speaker Corporation | Tracking and lighting systems and methods for a vehicle |
| DE102015013191A1 (de) * | 2015-10-10 | 2017-04-13 | Daimler Ag | Verfahren zum Betrieb einer Leuchteinheit und Leuchteinheit |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997009311A1 (de) * | 1995-09-07 | 1997-03-13 | F. Hoffmann-La Roche Ag | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz |
| US6197959B1 (en) * | 1999-04-27 | 2001-03-06 | Hoffmann-La Roche Inc. | Piperidine derivatives |
| US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
| US20040204455A1 (en) * | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| TW200833687A (en) * | 2005-03-31 | 2008-08-16 | Speedel Experimenta Ag | Substituted piperidines |
-
2006
- 2006-03-29 TW TW097113173A patent/TW200833687A/zh unknown
- 2006-03-29 TW TW095110894A patent/TW200716622A/zh unknown
- 2006-03-29 AR ARP060101217A patent/AR055756A1/es unknown
- 2006-03-30 BR BRPI0621969-1A patent/BRPI0621969A2/pt not_active IP Right Cessation
- 2006-03-30 JP JP2008503525A patent/JP2008534558A/ja active Pending
- 2006-03-30 CA CA002601702A patent/CA2601702A1/en not_active Abandoned
- 2006-03-30 PL PL06725445T patent/PL1863803T3/pl unknown
- 2006-03-30 US US11/887,227 patent/US20100029628A1/en not_active Abandoned
- 2006-03-30 WO PCT/EP2006/061197 patent/WO2006103277A2/en active Application Filing
- 2006-03-30 AT AT06725445T patent/ATE479681T1/de active
- 2006-03-30 DE DE602006016573T patent/DE602006016573D1/de active Active
- 2006-03-30 EP EP06725445A patent/EP1863803B1/en not_active Not-in-force
- 2006-03-30 PT PT06725445T patent/PT1863803E/pt unknown
- 2006-03-30 BR BRPI0608758-2A patent/BRPI0608758A2/pt not_active IP Right Cessation
-
2007
- 2007-09-20 IL IL186130A patent/IL186130A0/en unknown
-
2008
- 2008-02-05 AR ARP080100485A patent/AR065188A2/es not_active Application Discontinuation
- 2008-02-11 IL IL189429A patent/IL189429A0/en unknown
- 2008-03-14 US US12/076,221 patent/US7687495B2/en not_active Expired - Fee Related
- 2008-03-18 JP JP2008069369A patent/JP2008201787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL1863803T3 (pl) | 2011-02-28 |
| CA2601702A1 (en) | 2006-10-05 |
| EP1863803B1 (en) | 2010-09-01 |
| WO2006103277A2 (en) | 2006-10-05 |
| PT1863803E (pt) | 2010-11-18 |
| JP2008201787A (ja) | 2008-09-04 |
| ATE479681T1 (de) | 2010-09-15 |
| TW200716622A (en) | 2007-05-01 |
| US20080171748A1 (en) | 2008-07-17 |
| BRPI0608758A2 (pt) | 2009-07-07 |
| WO2006103277A3 (en) | 2006-12-28 |
| BRPI0621969A2 (pt) | 2011-07-19 |
| TW200833687A (en) | 2008-08-16 |
| US7687495B2 (en) | 2010-03-30 |
| IL189429A0 (en) | 2008-06-05 |
| JP2008534558A (ja) | 2008-08-28 |
| DE602006016573D1 (de) | 2010-10-14 |
| EP1863803A2 (en) | 2007-12-12 |
| IL186130A0 (en) | 2008-01-20 |
| AR055756A1 (es) | 2007-09-05 |
| US20100029628A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065188A2 (es) | Piperidinas sustituidas, preparacion farmaceutica y uso de dichas piperidinas para preparar medicamentos | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR062221A1 (es) | Imidazolidina-2,4- dionas sustituidas con arilaminoarilalquilo, medicamentos que comprenden estos compuestos y su uso | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| JP2008534558A5 (es) | ||
| AR046083A1 (es) | Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos | |
| WO2008007113A3 (en) | Pharmaceutical combinations | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| JP2008201787A5 (es) | ||
| NO20084742L (no) | Aziridinyl-epotilonforbindelser | |
| ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| NO20085169L (no) | Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| AR046269A1 (es) | Piperidinas sustituidas, procedimiento de preparacion y uso como inhibidores potentes de renina | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR072787A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR084001A1 (es) | Monobactamas y su uso en el tratamiento de infecciones bacterianas | |
| AR062095A1 (es) | Profarmaco de compuesto cinamida | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR070936A1 (es) | 1,2,4 -triazoles trisustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |